U.S. markets close in 5 hours 14 minutes

Jazz Pharmaceuticals plc (JAZZ)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
170.00+3.63 (+2.18%)
As of 10:46AM EDT. Market open.
Sign in to post a message.
  • j
    jim
    $SLS conversation
    Share price will steadily climb approaching the 2 Q2 seconds quarter Combination Trial Readouts
    -Just the Known Catalysts
    1 Gps Phase 3 Enrollment Update
    2 GPs Phase 2 Keytruda combination Results Q2 - Q2 is now
    3 Gps + Opdivo Mesothelioma Combination results also in Q2 - watch begins
    4 Nps Out License - over due
    5 Gps Euro License - any day now
    Tiny float, No debt, Multi-billion dollar market comps. In the past couple of years, after valuable trial data was released the share price would launch, and then shorts sold to cap the price expecting to cover with shares from an offering, so the price tanked -didn’t hold the value of real clinical data. That cycle is over - given the strong cash position $40M or so and microscopic burn rate of just $3.5/4M quarter and the $202m licensee already making payments.
    The earnings and cash pile will allow institutions to take a close look at the Phase 3 Assets value. They will see $SLS currently trades at a huge discount to actual market comps. $GLSI for Nelipepimut-S P3 TNBC and
    $jazz bought $cpxx for $1.5b when it extended survival to 5.95 months vs 21 months for Gps.
    $sls key drug Gps, extended survival to 21 months in the same exact patient setting.
    Yet this only trades for less than 7% of that?, when Gps treats 20 cancers in total.
    Price will continue to appreciate all along the way to the FDA Approval this time next year
    FDA APPROVAL $200+
  • E
    Ez$
    $SLS conversation
    Load in before this tiger runs - 2 phase 3 assets, a AML Phase 3 nearing completion, a Phase 3 Approval for TNBC, and DCIS, Direct Market comps of $1.5B Cpxx/ $JAZZ, $500M $GLSI, a $202M Licensee making payments, $40 M in cash $3.5M burn --> Huge $BMY $MRK Combination trial results for Mesothelioma Imminent - Just Keep stacking up for a huge Pay day
    EZ$
    Bullish
  • j
    jim
    Share price will steadily climb approaching the 2 Q2 seconds quarter Combination Trial Readouts
    -Just the Known Catalysts
    1 Gps Phase 3 Enrollment Update
    2 GPs Phase 2 Keytruda combination Results Q2 - Q2 is now
    3 Gps + Opdivo Mesothelioma Combination results also in Q2 - watch begins
    4 Nps Out License - over due
    5 Gps Euro License - any day now
    Tiny float, No debt, Multi-billion dollar market comps. In the past couple of years, after valuable trial data was released the share price would launch, and then shorts sold to cap the price expecting to cover with shares from an offering, so the price tanked -didn’t hold the value of real clinical data. That cycle is over - given the strong cash position $40M or so and microscopic burn rate of just $3.5/4M quarter and the $202m licensee already making payments.
    The earnings and cash pile will allow institutions to take a close look at the Phase 3 Assets value. They will see $SLS currently trades at a huge discount to actual market comps. $GLSI for Nelipepimut-S P3 TNBC and
    $jazz bought $cpxx for $1.5b when it extended survival to 5.95 months vs 21 months for Gps.
    $sls key drug Gps, extended survival to 21 months in the same exact patient setting.
    Yet this only trades for less than 7% of that?, when Gps treats 20 cancers in total.
    Price will continue to appreciate all along the way to the FDA Approval this time next year
    FDA APPROVAL $200+
  • j
    jim
    $SLS conversation
    Bottom in will steadily climb approaching the Two Q2 second quarter Combination Trial Readouts
    -Just the Known Catalysts
    1 Gps Phase 3 Enrollment Update
    2 GPs Phase 2 Keytruda combination Results Q2 - Q2 is now
    3 Gps + Opdivo Mesothelioma Combination results also in Q2 - watch begins
    4 Nps Out License - over due
    5 Gps Euro License - any day now
    Tiny float, No debt, Multi-billion dollar market comps. In the past couple of years, after valuable trial data was released the share price would launch, and then shorts sold to cap the price expecting to cover with shares from an offering, so the price tanked -didn’t hold the value of real clinical data. That cycle is over - given the strong cash position $40M or so and microscopic burn rate of just $3.5/4M quarter and the $202m licensee already making payments.
    The earnings and cash pile will allow institutions to take a close look at the Phase 3 Assets value. They will see $SLS currently trades at a huge discount to actual market comps. $GLSI for Nelipepimut-S P3 TNBC and
    $jazz bought $cpxx for $1.5b when it extended survival to 5.95 months vs 21 months for Gps.
    $sls key drug Gps, extended survival to 21 months in the same exact patient setting.
    Yet this only trades for less than 7% of that?, when Gps treats 20 cancers in total.
    Price will continue to appreciate all along the way to the FDA Approval this time next year
    FDA APPROVAL $200+
    Bullish
  • j
    jim
    The earnings and cash pile will allow institutions to take a close look at the Phase 3 Assets value. They will see $SLS currently trades at a huge discount to actual market comps. $GLSI for Nelipepimut-S P3 TNBC and
    $jazz bought $cpxx for $1.5b when it extended survival to 5.95 months vs 21 months for Gps.
    $sls key drug Gps, extended survival to 21 months in the same exact patient setting.
    Yet this only trades for less than 7% of that?, when Gps treats 20 cancers in total.
    Price will continue to appreciate all along the way to the FDA Approval this time next year
    FDA APPROVAL $200+
  • j
    jim
    Share price will steadily climb approaching the 2 Q2 seconds quarter Combination Trial Readouts
    -Known Catalysts
    Gps Phase 3 Enrollment Update
    GPs Phase 2 Keytruda combination Results Q2 - Q2 is now
    Gps + Opdivo Mesothelioma Combination results also in Q2 - watch begins
    Nps Out License - over due
    Gps Euro License - any day now
    Tiny float, No debt, Multi-billion dollar market comps. In the past couple of years, after valuable trial data was released the share price would launch, and then shorts sold to cap the price expecting to cover with shares from an offering, so the price tanked -didn’t hold the value of real clinical data. That cycle is over - given the strong cash position $40M or so and microscopic burn rate of just $3.5/4M quarter and the $202m licensee already making payments.
    The earnings and cash pile will allow institutions to take a close look at the Phase 3 Assets value. They will see $SLS currently trades at a huge discount to actual market comps. $GLSI for Nelipepimut-S P3 TNBC and
    $jazz bought $cpxx for $1.5b when it extended survival to 5.95 months vs 21 months for Gps.
    $sls key drug Gps, extended survival to 21 months in the same exact patient setting.
    Yet this only trades for less than 7% of that?, when Gps treats 20 cancers in total.
    Price will continue to appreciate all along the way to the FDA Approval this time next year
    FDA APPROVAL $200+
  • I
    Immunotrader 10
    $SLS conversation
    SLS has a tiny float, No Debt, 2 Valuable Phase 3 Assets with Market comps of $800M $GLSI, and $CPXX was bought for $1.5B by $jazz - $SLS has tons of room to RUN - Phase 3 assets with a $200M Licensee already making payments, $40M is in the bank, tiny $3.5m q burn rate, 2 Massive combination trials now due $BMY and $MRK + FDA Approval and a multibillion market cap in less than a year. Triple DIGITS are in SLS's Future
    Bullish
  • j
    jim
    $SLS conversation
    Share price will steadily climb approaching the 2 Q2 Combination Trial Readouts -Known Catalysts
    Gps Phase 3 Enrollment Update
    GPs Phase 2 Keytruda combination Results Q2 - Q2 is now
    Gps + Opdivo Mesothelioma Combination results also in Q2 - watch begins
    Nps Out License - over due
    Gps Euro License - any day now
    Tiny float, No debt, Multi-billion dollar market comps. In the past couple of years, after valuable trial data was released the share price would launch, and then shorts sold to cap the price expecting to cover with shares from an offering, so the price tanked -didn’t hold the value of real clinical data. That cycle is over - given the strong cash position $40M or so and microscopic burn rate of just $3.5/4M quarter and the $202m licensee already making payments.
    The earnings and cash pile will allow institutions to take a close look at the Phase 3 Assets value. They will see $SLS currently trades at a huge discount to actual market comps. $GLSI for Nelipepimut-S P3 TNBC and
    $jazz bought $cpxx for $1.5b when it extended survival to 5.95 months vs 21 months for Gps.
    $sls key drug Gps, extended survival to 21 months in the same exact patient setting.
    Yet this only trades for less than 7% of that?, when Gps treats 20 cancers in total.
    Price will continue to appreciate all along the way to the FDA Approval this time next year
    FDA APPROVAL $200+
  • E
    Ez$
    $SLS conversation
    Thank you $XBI 2 phase 3 assets, a AML Phase 3 nearing completion, a Phase 3 Approval for TNBC, and DCIS, Direct Market comps of $1.5B Cpxx/ $JAZZ, $500M $GLSI, a $202M Licensee making payments, $40 M in cash a tiny $3.5M Q burn --> Huge $BMY $MRK Combination trial results for Mesothelioma Imminent - Just Keep stacking up for a huge Pay day
    EZ$
    Bullish
    Bullish
  • j
    jim
    Tiny float, No debt, Multi-billion dollar market comps. In the past couple of years, after valuable trial data was released the share price would launch, and then shorts sold to cap the price expecting to cover with shares from an offering, so the price tanked -didn’t hold the value of real clinical data. That cycle is over - given the strong cash position $40M or so and microscopic burn rate of just $3.5/4M quarter and the $202m licensee already making payments.
    The earnings and cash pile will allow institutions to take a close look at the Phase 3 Assets value. They will see $SLS currently trades at a huge discount to actual market comps. $GLSI for Nelipepimut-S P3 TNBC and
    $jazz bought $cpxx for $1.5b when it extended survival to 5.95 months vs 21 months for Gps.
    $sls key drug Gps, extended survival to 21 months in the same exact patient setting.
    Yet this only trades for less than 7% of that?, when Gps treats 20 cancers in total.
    Share price will steadily climb approaching the FDA APPROVAL $200+
  • j
    jim
    strong cash position $40M or so and microscopic burn rate of just $3.5/4M quarter and the $202m licensee already making payments.
    The earnings and cash pile will allow institutions to take a close look at the Phase 3 Assets value. They will see $SLS currently trades at a huge discount to actual market comps. $GLSI for Nelipepimut-S P3 TNBC and
    $jazz bought $cpxx for $1.5b when it extended survival to 5.95 months vs 21 months for Gps.
    $sls key drug Gps, extended survival to 21 months in the same exact patient setting.
    Yet this only trades for less than 7% of that?, when Gps treats 20 cancers in total.
    Price will continue to appreciate all along the way to the FDA Approval this time next year
    FDA APPROVAL $200+
  • j
    jim
    $SLS conversation
    Some of what may have caused the run earlier: price will steadily climb approaching the FDA APPROVAL $200+
    Known Catalysts - M-Vest Audio with Nps Licensing discussion
    Gps Phase 3 Enrollment Update
    GPs Phase 2 Keytruda combination Results Q2 - Q2 is now
    Gps + Opdivo Mesothelioma Combination results also in Q2 - watch begins
    Nps Out License - over due
    Gps Euro License - any day now
    Tiny float, No debt, Multi-billion dollar market comps. In the past couple of years, after valuable trial data was released the share price would launch, and then shorts sold to cap the price expecting to cover with shares from an offering, so the price tanked -didn’t hold the value of real clinical data. That cycle is over - given the strong cash position $40M or so and microscopic burn rate of just $3.5/4M quarter and the $202m licensee already making payments.
    The earnings and cash pile will allow institutions to take a close look at the Phase 3 Assets value. They will see $SLS currently trades at a huge discount to actual market comps. $GLSI for Nelipepimut-S P3 TNBC and
    $jazz bought $cpxx for $1.5b when it extended survival to 5.95 months vs 21 months for Gps.
    $sls key drug Gps, extended survival to 21 months in the same exact patient setting.
    Yet this only trades for less than 7% of that?, when Gps treats 20 cancers in total.
  • j
    jim
    $SLS conversation
    Known Catalysts - M-Vest Audio with Nps Licensing discussion
    Gps Phase 3 Enrollment Update
    GPs Phase 2 Keytruda combination Results Q2 - Q2 is now
    Gps + Opdivo Mesothelioma Combination results also in Q2 - watch begins
    Nps Out License - over due
    Gps Euro License - any day now
    Tiny float, No debt, Multi-billion dollar market comps. In the past couple of years, after valuable trial data was released the share price would launch, and then shorts sold to cap the price expecting to cover with shares from an offering, so the price tanked -didn’t hold the value of real clinical data. That cycle is over - given the strong cash position $40M or so and microscopic burn rate of just $3.5/4M quarter and the $202m licensee already making payments.
    The earnings and cash pile will allow institutions to take a close look at the Phase 3 Assets value. They will see $SLS currently trades at a huge discount to actual market comps. $GLSI for Nelipepimut-S P3 TNBC and
    $jazz bought $cpxx for $1.5b when it extended survival to 5.95 months vs 21 months for Gps.
    $sls key drug Gps, extended survival to 21 months in the same exact patient setting.
    Yet this only trades for less than 7% of that?, when Gps treats 20 cancers in total.
    Share price will steadily climb approaching the FDA APPROVAL $200+
    Bullish
  • j
    jim
    Share price will steadily climb approaching the 2 Q2 Combination Trial Readouts w/ $bmy & Mrk Known Catalysts:
    Gps Phase 3 Enrollment Update
    GPs Phase 2 Keytruda combination Results Q2 - Q2 is now
    Gps + Opdivo Mesothelioma Combination results also in Q2 - watch begins
    Nps Out License - over due
    Gps Euro License - any day now
    Tiny float, No debt, Multi-billion dollar market comps. In the past couple of years, after valuable trial data was released the share price would launch, and then shorts sold to cap the price expecting to cover with shares from an offering, so the price tanked -didn’t hold the value of real clinical data. That cycle is over - given the strong cash position $40M or so and microscopic burn rate of just $3.5/4M quarter and the $202m licensee already making payments.
    The earnings and cash pile will allow institutions to take a close look at the Phase 3 Assets value. They will see $SLS currently trades at a huge discount to actual market comps. $GLSI for Nelipepimut-S P3 TNBC and
    $jazz bought $cpxx for $1.5b when it extended survival to 5.95 months vs 21 months for Gps.
    $sls key drug Gps, extended survival to 21 months in the same exact patient setting.
    Yet this only trades for less than 7% of that?, when Gps treats 20 cancers in total.
    Price will continue to appreciate all along the way to the FDA Approval this time next year
    FDA APPROVAL $200+
  • I
    Immunotrader 10
    $SLS conversation
    Tiny market cap for this - Should be closing over 10
    SLS has a tiny float, No Debt, 2 Valuable Phase 3 Assets with Market comps of $800M $GLSI, and $CPXX was bought for $1.5B by $jazz - $SLS has tons of room to RUN - Phase 3 assets with a $200M Licensee already making payments, $40M is in the bank, tiny $3.5m q burn rate, 2 Massive combination trials now due $BMY and $MRK + FDA Approval and a multibillion market cap in less than a year. Triple DIGITS are in SLS's Future
  • C
    Cured
    $SLS conversation
    Lock some away and wait for the payday
    https://www.biopharmadive.com/news/jazz-pharma-snaps-up-leukemia-drug-with-15-billion-deal-for-celator/420060/ $CPXX was bought by $jazz for $1.5b (with a b) after extending overall survival to 9months in the same patient setting. 10K now confirms sls has all the cash to get well past the FDA Approval and a multibillion market cap - unless they are bought out first - which will most likely happen. GPS -The final analysis now shows that GPS extends patients’ overall survival to 21 months, after a median follow-up of 30.8 months. The vaccine continued to be well-tolerated throughout the entire study.

    “These follow-up data build upon the initially published clinical results from the Phase 1/2 study of GPS in AML patients in CR2 and provide further evidence that this novel immunotherapeutic vaccine approach may improve outcomes for patients in this setting, who often harbor measurable residual disease and have a poor prognosis if they are unable to undergo allotransplant,” said Javier Pinilla-Ibarz, MD, PhD, principal investigator of the trial. Pinilla-Ibarz also is the director of Immunotherapy for Malignant Hematology at the Moffitt Cancer Center in. Tampa, Florida.

    Building upon these positive results Sella launched the Phase 3 REGAL trial (NCT04229979), which is currently enrolling patients.

    This open-label study will recruit about 116 AML patients in complete remission after a second-line treatment, who will be assigned randomly to either maintenance therapy with GPS or the physician’s choice of best available treatment.
  • C
    Cured
    $SLS conversation
    Lock some away and wait for the payday
    https://www.biopharmadive.com/news/jazz-pharma-snaps-up-leukemia-drug-with-15-billion-deal-for-celator/420060/ $CPXX was bought by $jazz for $1.5b (with a b) after extending overall survival to 9months in the same patient setting. 10K now confirms sls has all the cash to get well past the FDA Approval and a multibillion market cap - unless they are bought out first - which will most likely happen. GPS -The final analysis now shows that GPS extends patients’ overall survival to 21 months, after a median follow-up of 30.8 months. The vaccine continued to be well-tolerated throughout the entire study.

    “These follow-up data build upon the initially published clinical results from the Phase 1/2 study of GPS in AML patients in CR2 and provide further evidence that this novel immunotherapeutic vaccine approach may improve outcomes for patients in this setting, who often harbor measurable residual disease and have a poor prognosis if they are unable to undergo allotransplant,” said Javier Pinilla-Ibarz, MD, PhD, principal investigator of the trial. Pinilla-Ibarz also is the director of Immunotherapy for Malignant Hematology at the Moffitt Cancer Center in. Tampa, Florida.

    Building upon these positive results Sella launched the Phase 3 REGAL trial (NCT04229979), which is currently enrolling patients.

    This open-label study will recruit about 116 AML patients in complete remission after a second-line treatment, who will be assigned randomly to either maintenance therapy with GPS or the physician’s choice of best available treatment.
  • C
    Cured
    $SLS conversation
    https://www.biopharmadive.com/news/jazz-pharma-snaps-up-leukemia-drug-with-15-billion-deal-for-celator/420060/ $CPXX was bought by $jazz for $1.5b (with a b) after extending overall survival to 9months in the same patient setting. 10K now confirms sls has all the cash to get well past the FDA Approval and a multibillion market cap - unless they are bought out first - which will most likely happen. GPS -The final analysis now shows that GPS extends patients’ overall survival to 21 months, after a median follow-up of 30.8 months. The vaccine continued to be well-tolerated throughout the entire study.

    “These follow-up data build upon the initially published clinical results from the Phase 1/2 study of GPS in AML patients in CR2 and provide further evidence that this novel immunotherapeutic vaccine approach may improve outcomes for patients in this setting, who often harbor measurable residual disease and have a poor prognosis if they are unable to undergo allotransplant,” said Javier Pinilla-Ibarz, MD, PhD, principal investigator of the trial. Pinilla-Ibarz also is the director of Immunotherapy for Malignant Hematology at the Moffitt Cancer Center in. Tampa, Florida.

    Building upon these positive results Sella launched the Phase 3 REGAL trial (NCT04229979), which is currently enrolling patients.

    This open-label study will recruit about 116 AML patients in complete remission after a second-line treatment, who will be assigned randomly to either maintenance therapy with GPS or the physician’s choice of best available treatment.
  • j
    jim
    $SLS conversation
    Reposting for vector-aka-dmanakajason) Quadruple +++ Soon Triple Digits this year from Upcoming Catalysts
    1.a Wednesday March 17th MVEST Meeting
    1. Pr announcing Annual Meeting is Now officially due
    2. Upside Earnings beat with Positive net income - 1Day
    3. GLSI like Nps trial Results are imminent truly imminent - Any day now
    4. Gps Phase 3 Enrollment Complete announcement - Any day now
    4.a GPs Phase 2 Keytruda combination Results Q2 - Watch Begins 2 weeks
    4.b Gps + Opdivo Mesothelioma Combination results Q2 - watch begins in 2 weeks
    5. Nps Out License - over due
    6. Gps Euro License - any day now
    7. More Milestone Money - any day now
    a quick list of known valuable catalysts
    Tiny float, No debt, Multi-billion and market comps. In the past couple of years, after valuable trial data was released the price would launch, shorts expected to cover with shares from an offering, so the price tanked -didn’t hold the value of real clinical data. That cycle is over - given the strong cash position $40M or so and microscopic burn rate of $3.5/4M quarter and the $202m licensee already paying.
    The earnings and cash pile announcement will motivate institutions to take a look at the Assets value. They will see $SLS currently trades at a huge discount to actual market comps.
    $jazz bought $cpxx for $1.5b when it extended survival to 5.95 months vs 21 months for Gps.
    $sls key drug Gps, extended survival to 21 months in the same exact patient setting.
    Yet this only trades for less than 8% of that?
    Gps treats 20 cancers in total.
    $200 per share this year on P3 Fda review
  • j
    jamboree
    $SLS conversation
    $CPXX bought by $JAZZ - Great Efficacy Comp Data / Market size info stats this street(sorry)article B4 the buyout.
    Gps extended Overall to 21 months for these patients: More than 300 elderly patients with secondary (high risk) AML were randomized equally to treatment with Vyxeos or the 7+3 regimen. The primary endpoint of the study was overall survival.

    Celator was proven right. Treatment with Vyxeos reduced the risk of death by 31% compared to 7+3. The survival benefit favoring Vyxeos -- 3.6 months at the median -- was statistically significant, achieving the primary endpoint of the study. ( Sls is 5x better than this $1.5B drug )

    As you can see below give the market size for GPs, $SLS is Undervalued by 10x
    Celator believes it can achieve U.S. and European Vyxeos sales in the range of $200 million to $270 million based on the subset of AML patients enrolled in the phase III study. If use of Vyxeos is expanded into other AML patient populations, peak sales could reach $690 million to $780 million, the company estimates.
    https://www.thestreet.com/investing/stocks/celator-pharma-surprises-with-blood-cancer-drug-survival-benefit-13494703
    Based on the positive study results, Celator expects to seek regulatory approval for Vyxeos in the U.S. and Europe later this year.
    Based on the positive study results, Celator expects to seek regulatory approval for Vyxeos in the U.S. and Europe later this year.
    www.thestreet.com